Planning and Evaluation ABSTRACT Under the leadership of the Director, Brian Druker, rigorous planning and evaluation efforts continue to be a critical activity, focused on the ongoing growth and development of the OHSU Knight Cancer Institute (Knight). Druker shares the responsibility for establishing the vision and strategic plans with the Knight Senior Leadership composed of Tomasz Beer, M.D. (Deputy Director and Interim Associate Director Clinical Research), Lisa Coussens, Ph.D. (Associate Director Basic Research), Sara Courtneidge, Ph.D. (Associate Director Translational Research), Joe Gray, Ph.D. (Associate Director Biophysical Oncology), Ray Bergan, M.D. (Associate Director Medical Oncology), Kristin Bialobok, M.S.N (Associate Director Administration), and Mary Stenzel-Poore, Ph.D. (School of Medicine Associate Dean, Research). This group, together with external advisors, undertook extensive strategic planning and evaluation efforts with the goal of enhancing the productivity of our center. Three committees are responsible for the internal governance of the Knight: the Associate Directors Advisory Group, the Program Leaders and Shared Resource Directors Committee, and the Clinical Executive Group. These committees are structured to ensure successful operation of the Knight, support new initiatives and to promote interactions within and between programmatic elements of the Knight. The External Advisory Board (EAB) is a distinguished group of cancer specialists and is chaired by Dr. Joseph Simone. The EAB reviews the Knight's scientific progress, vision, and future plans. Further ad hoc discussions may occur between the Director and EAB members throughout the year. The EAB reviews the organizational structure, programs, and shared resources providing advice regarding whether each is adding value to the institute's mission. They evaluate scientific excellence, focus, and interactivity of each program. The EAB provides formal reports to the Director, which are shared with the OHSU President and Dean of the SOM. The recommendations of this group have been essential in developing our current leadership and program structure, and shared resources. The EAB has consistently helped us develop a programmatic structure that optimally aligns with the strengths of our institute, optimizes the capacity of programs to create trans-disciplinary studies, and supports inter-programmatic interactions. To engage the Knight membership in strategic planning, and to stimulate intra- and inter-programmatic member interactions, routine programmatic meetings, as well as a number of Knight-wide and programmatic retreats were held. Development Funds, in the form of pilot project awards, were provided to stimulate collaborative publications and multi-investigator grants. This investment and planning has successfully resulted in an overall member collaborative publication rate of 39%, as well as a significant increase in multi-investigator grants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-20
Application #
9640126
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828

Showing the most recent 10 out of 277 publications